Obesity phase 2
Zhou Z, Cheng Z, Jin P, et al. “UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.” Cell Metabolism, 2026.
Type 2 diabetes companion study
Cell Metabolism · DOI: 10.1016/j.cmet.2026.10.010. Registrations: NCT07163624 and CTR20250029.
Retatrutide context
Jastreboff et al., NEJM, 2023. DOI: 10.1056/NEJMoa2301972; PMID 37366315; NCT04881760. A separate US trial, not a comparator arm in the UBT251 study.
Editorial context
CT632 on UBT251 and CT632 on retatrutide provide companion reading. PeptIQ’s retatrutide introduction is from our related brand. These are secondary editorial links, not substitutes for primary evidence.
Provenance and limits
The numerical dataset is transcribed from the project’s supplied FACTS.md extract, which attributes the obesity figures to the paper’s Table 2 and abstract. Live full-text retrieval could not be completed during this build. Registry status is the supplied editorial snapshot. No unlisted secondary-endpoint deltas have been added.